- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02517931
Sphenopalatine Ganglion Block for Postdural Puncture Headache in the Emergency Department
September 23, 2019 updated by: University of Arkansas
Sphenopalatine Ganglion Block for Treatment of Postdural Puncture Headache in the Emergency Department: A Prospective, Randomized, Double-Blind Placebo Controlled Study
This study evaluates sphenopalatine ganglion block (SPGB) for the treatment of postdural puncture headache (PDPH) in the emergency department (ED).
Half of the patients will receive a true nerve block with lidocaine and bupivacaine.
The other half will receive a placebo nerve block.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
Postdural puncture headaches (PDPH) are a common consequence of diagnostic lumbar puncture.
The gold standard treatment for a PDPH is currently an autologous epidural blood patch (AEBP), which involves placing a needle into the epidural space of the spine and then injecting 20 ml of the patients own blood through the needle and into the epidural space to form a clot over the tear in the tissue layer that causes the headache.
This is an invasive procedure that carries risks of pain, bleeding, infection, and in rare cases, neurological complications.
We want to test the efficacy of using a less invasive procedure, called a sphenopalatine ganglion block (SPGB), for treatment of PDPH.
SPGB has been used for many years in the treatment of migraines and cluster headaches, and there are several case reports of its use to successfully treat PDPH as well.
SPGB simply involves applying a local anesthetic to the mucosa in the back of each nostril to numb the nerves that cause the headache.
We hope that the SPGB will reduce the number of PDPH patients that require an AEBP.
Study Type
Interventional
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72202
- University of Arkansas for Medical Sciences
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Active postdural puncture headache within 7 days after diagnostic lumbar puncture
- Age ≥ 18 years.
- American Society of Anesthesiologists (ASA) physical status ≤ 3
Exclusion Criteria:
- Known coagulopathy
- Known nasal septal deviation or abnormalities
- Medical conditions contraindicated to lidocaine or bupivacaine
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Sphenopalatine Ganglion Block
Subjects will be asked to blow out each nostril.
They will then be laid supine with a small shoulder roll and intranasal phenylephrine 0.25% (RhinallⓇ) will be sprayed once into each nostril to preemptively minimize bleeding.
Sphenopalatine ganglion block will be performed by inserting long cotton tipped applicators saturated in 2% viscous lidocaine into nostril until properly seated in the posterior nasopharynx.
These will be left in place for 10 minutes and then 1 mililiter of 0.5% bupivacaine will be administered down the plastic hollow shaft of each applicator via an 18g angiocatheter.
The applicators will remain in place for 10 more minutes and then be removed.
|
Subjects will be asked to blow out each nostril.
They will then be laid supine with a small shoulder roll and intranasal phenylephrine 0.25% (RhinallⓇ) will be sprayed once into each nostril to preemptively minimize bleeding.
SPGB will be performed by inserting long cotton tipped applicators saturated in 2% viscous lidocaine into nostril until properly seated in the posterior nasopharynx.
These will be left in place for 10 minutes and then 1mL of 0.5% bupivacaine will be administered down the plastic hollow shaft of each applicator via an 18g angiocatheter.
The applicators will remain in place for 10 more minutes and then be removed.
|
PLACEBO_COMPARATOR: Placebo
Subjects will be asked to blow out each nostril.
They will then be laid supine with a small shoulder roll and intranasal phenylephrine 0.25% (RhinallⓇ) will be sprayed once into each nostril to preemptively minimize bleeding.
SPGB will be performed by inserting long cotton tipped applicators saturated in carboxymethylcellulose based lubricant (i.e.
K-Y Jelly®) into nostril until properly seated in the posterior nasopharynx.
These will be left in place for 10 minutes and then 1 mililiter of normal saline will be administered down the plastic hollow shaft of each applicator via an 18g angiocatheter.
The applicators will remain in place for 10 more minutes and then be removed.
|
Subjects will be asked to blow out each nostril.
They will then be laid supine with a small shoulder roll and intranasal phenylephrine 0.25% (RhinallⓇ) will be sprayed once into each nostril to preemptively minimize bleeding.
SPGB will be performed by inserting long cotton tipped applicators saturated in carboxymethylcellulose based lubricant (i.e.
K-Y Jelly®) into nostril until properly seated in the posterior nasopharynx.
These will be left in place for 10 minutes and then 1 mililiter of normal saline will be administered down the plastic hollow shaft of each applicator via an 18g angiocatheter.
The applicators will remain in place for 10 more minutes and then be removed.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain level with Verbal Rating Scale
Time Frame: 5 days
|
Patients will be asked to self rate their pain with 0 as no pain at all up to 10 being the worst pain imaginable.
|
5 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Carly Eastin, MD, University of Arkansas
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
January 1, 2019
Primary Completion (ACTUAL)
September 23, 2019
Study Completion (ACTUAL)
September 23, 2019
Study Registration Dates
First Submitted
August 5, 2015
First Submitted That Met QC Criteria
August 6, 2015
First Posted (ESTIMATE)
August 7, 2015
Study Record Updates
Last Update Posted (ACTUAL)
September 25, 2019
Last Update Submitted That Met QC Criteria
September 23, 2019
Last Verified
September 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 204502
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Postdural Puncture Headache
-
Nantes University HospitalCompletedPostdural Puncture HeadacheFrance
-
The University of Texas Health Science Center,...WithdrawnPost-Lumbar Puncture HeadacheUnited States
-
Samuel Lunenfeld Research Institute, Mount Sinai...CompletedPostdural Puncture HeadacheCanada
-
Al-Azhar UniversityBenha UniversityRecruiting
-
Ain Shams UniversityNot yet recruitingPostdural Puncture HeadacheEgypt
-
Benha UniversityCompletedPostdural Puncture HeadacheEgypt
-
United States Naval Medical Center, San DiegoUnited States Naval Medical Center, PortsmouthCompletedPostdural Puncture Headache
-
Ain Shams UniversityCompleted
-
Ain Shams UniversityCompleted
-
Ain Shams UniversityCompletedPostdural Puncture HeadacheEgypt
Clinical Trials on Sphenopalatine Ganglion Block
-
Beijing Tongren HospitalCompleted
-
New York State Psychiatric InstituteCompleted
-
Istanbul Medeniyet UniversityCompleted
-
New York State Psychiatric InstituteSuspended
-
Ajou University School of MedicineCompletedSphenopalatine Ganglion BlockKorea, Republic of
-
Beijing Tongren HospitalCompleted
-
BrainsGateCompletedIschemic StrokeIsrael, Hong Kong, Denmark, Spain, France, Finland, United States, Serbia, Czechia, Italy, Portugal, Germany, Georgia, Poland, Canada, North Macedonia, Slovakia, Ukraine
-
University Hospital of FerraraRecruitingPost Operative Pain | Craniofacial PainItaly
-
Universidade Federal FluminenseUnknownPostoperative Pain | Anesthesia, Local | SurgeryBrazil
-
Brasilia University HospitalTerminatedPost-Dural Puncture HeadacheBrazil